Home' Australian Pharmacist : Australian Pharmacist July 2013 Contents 80
Australian Pharmacist July 2013 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Australian Pharmacist is a professional journal providing community pharmacists with a
range of peer reviewed articles that are interesting and evidence-based to ensure credibility
and accuracy. The journal has an extremely strong CPD program followed by nearly 10,000
pharmacists and a typical monthly article receives more than 2950 assessments, with highs
Read in greater detail and more regularly than any other pharmacy title – such constant
behaviour means you can count on our readers to open any issue and be seen!
» Read by 65% of community pharmacists
» The most valued and used for clinical information, continuing education, prescription
medicines, scheduled medicines, professional services and patient counselling
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2012
Adding the best read pages in pharmacy media to your campaign will result in greater
impact, leading to greater recognition – package with the Australian Pharmacist
eBulletin to gain further recognition with 12,000 community pharmacists and high
open rates of 30%.
Ph: 02 9988 4689
Ph: 02 9547 3001
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
after four weeks of treatment with
tadalafil 5 mg.5
In a placebo-controlled study of 606
sexually active men aged 45 years and
older who had ED and LUTS associated
with an enlarged prostate, tadalafil 5 mg
significantly improved both ED and LUTS
outcomes through 12 weeks.6
Associate Professor Henry Woo, Sydney
urological surgeon said: ‘The approval
of tadalafil 5 mg offers men another
treatment option for a condition that
becomes more prevalent with age.
Urinary problems may have a profound
impact on a man’s quality of life.
As men age, the severity of their urinary
symptoms and degree of bother often
increases. Many men have to adjust their
life to accommodate more frequent, and
often urgent, bathroom visits.
‘Health professionals should discuss
LUTS with their patients, particularly
as urinary symptoms can be a sign of
prostate problems and warrant further
investigation,’ Dr Woo said.
1. Eli Lilly Australia. Approved product information for Cialis. 2013.
2. Rosen R, et al. Lower urinary tract symptoms and male sexual
dysfunction: The multinational survey of the aging male
(MSAM-7). European Urology 2003;44:637–49.
3. Holden CA et al. Men in Australia Telephone Survey (MATeS): a
national survey of the reproductive health concerns of middle-
aged and older Australian men. Lancet 2005;366:218–24.
4. Abrams P, et al. The Standardisation of Terminology of Lower
Urinary Tract Function: Report from the Standardisation Sub-
committee of the International Continence Society. Neurology
and Urodynamics 2002:21:167–78.
5. Roehrborn C, et al. Tadalafil Administered Once Daily for
Lower Urinary Tract Symptoms Secondary to Benign Prostatic
Hyperplasia: A Dose Finding Study. Journal of Urology
6. Egerdie RB, et al. Tadalafil 2.5 or 5 mg Administered Once Daily
for 12 Weeks in Men with Both Erectile Dysfunction and Signs
and Symptoms of Benign Prostatic Hyperplasia: Results of a
Randomized, Placebo-Controlled, Double-Blind Study. The
Journal of Sexual Medicine 2012;9:271–81.
Green-lipped mussel oil may play a role
in boosting the sports performance of
people with exercise induced asthma (EIA)
according to the lead researcher of a new
study that links the oil with improved lung
function and a reduction in medication
use for individuals with the condition.
The research showed a diet
supplemented with green-lipped mussel
oil can improve lung function by 57% and
reduce medication use in individuals with
exercise induced asthma.1
Exercise induced asthma is a common
condition characterised by wheezing,
coughing, and a tight chest in response
to exercise. It impacts around four
million Australians, both asthmatic and
non-asthmatic, who generally use puffers
to control the condition.2–4
In Australia, lead researcher and Olympic
triathlete Professor Tim Mickleborough
said the findings provided a potential
solution to help Australians with exercise
induced asthma reduce medication use,
enjoy exercise and possibly boost their
sports performance. What we’ve shown
is that taking green-lipped mussel oil can
improve lung function and reduce use
of medication. Anything you can do to
reduce the need for medication is huge’.
Results from the randomised,
placebo-controlled crossover study
are published in the July 2013 issue
of Respiratory Medicine. The Indiana
University study revealed after three
weeks of taking PCSO-524TM (Lyprinol)
• A decrease in the use of rescue
medication by an average of
5–10 puffs a day
• A 57% improvement in lung function
after an airway challenge test
• Improvements in asthma
symptom scores and peak flow
• A decrease in airway inflammation
markers after an airway challenge test.
Prof. Mickleborough’s study was supported
by a grant from Pharmalink, which
manufactures and owns PCSO-524TM.
Pharmalink had no role in study design,
data collection, data analysis, in writing the
journal article, or the decision to publish.
1. Marine lipid fraction PCSO-524TM (Lyprinol®/Omega XL®) of the
New Zealand green lipped mussel attenuates hyperpnea-
induced bronchoconstriction in asthma. Respir Med. 2013 May
6. pii: S0954-6111(13)00139-X . doi: 10.1016/j.rmed.2013.04.010.
[Epub ahead of print]
2. Maurer M, Simonett D, Brutsche MH. Challenge of exercise-
induced asthma and exercise-induced bronchoconstriction.
Expert Review of Respiratory Medicine, Feb 2009;3(1):13–19.
3. National Asthma Council of Australia. At: www.nationalasthma.
4. Am Fam Physician. Aug 152011;84(4):427–34.
Links Archive Australian Pharmacist June 2013 Australian Pharmacist August 2013 Navigation Previous Page Next Page